Abzena

Abzena is the leading end-to-end bioconjugate (ADCs, AOCs, RDCs) and complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services that de-risk and streamline the development of new medicines for patients in need. With over two decades of experience, 2000+ conjugates developed and over 200+ cell lines developed, we have the expertise and technical know-how to rapidly progress your biopharmaceutical to IND and beyond. And with footholds in the US and UK, we offer a simplified and secure supply chain.

Fully integrated CDMO+CRO support across multiple modalities:

-Monoclonal Antibodies (mAbs)

-Antibody-Drug Conjugates (ADCs)

-Antibody-Oligonucleotide Conjugates (AOCs)

-Radionuclide Antibody-Conjugates (RACs) & Radionuclide Drug-Conjugates (RDCs)

-Bispecific Antibodies (bsAbs)

-Fusion Proteins -Cytokines

-Recombinant & Conjugate Vaccines

-Nanoparticles

With Capabilities Ranging From:

• Early-Stage Research & Discovery, Design and Lead Selection

• Robust Analytics, Bioassays, and Immunogenicity

• Bioconjugation & Chemistry

• Antibody Engineering and Developability

• Mammalian Cell Line Development

• Linker Payload Design and Synthesis

• Analytical Method & Formulation Development

• Process Development and cGMP Manufacturing up to 2000L

• Technology Transfer & Scale-Up

• Regulatory Support

- Over 24 years of experience developing 2000+ conjugations, 1400+ linker-payloads synthesized and 200+ cell lines

-Champion Award Winner in Global Biologics at the 2025 CDMO Leadership Awards

- Unique end-to-end value proposition ranging from antibody discovery to clinical-scale GMP biologic drug substance manufacture

- Scientific expertise to deliver at high quality, low cost and compressed timelines

- Global customer base, including most of the top 20 biopharmaceutical companies

-Supply chain security with fully integrated US & UK facilities that can handle highly potent and cytotoxic molecules.

- 14 products utilizing Abzena’s technologies in clinical trials

- Biologics discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale.

- Bioconjugate (including ADCs, AOCs, RDCs) discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale.

- Synthesis, analysis, and GMP manufacture of APIs, payloads, and highly potent compounds (HPAPI) and cytotoxic

- Discovery to Phase II accelerated development for antibody-drug conjugates including antibodies, linkers and payloads.

-Tech transfer and commercial scale manufacturing up to 2000L for biologics and bioconjugates